Biotechnology company, Prothena, has announced positive topline P1 SAD study results for PRX005, an investigational tri-epitopic antibody for the treatment of Alzheimer’s disease.
Vector BioMed, a CDMO specializing in the manufacture of lentiviral vectors, launched this week; its first financing round was led by Viking Global Investors and Casdin Capital.